Drug recall · October 11, 2023
Oxybutynin Chloride Extended-Release Tablets USP 10 mg recall
Why: Failed Dissolution Specifications
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 68382-256-01) and b) 500 tablets (NDC 68382-256-05) bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534
- Lots / codes
Lot#: M300652 and M300651, exp. Dec 2024
- Quantity
- 7,248 bottles
- Company
- Zydus Pharmaceuticals (USA) Inc, Pennington, NJ
- Distribution
- Nationwide in the USA.
- Initiated
- September 21, 2023 · Voluntary: Firm initiated
- Classified
- October 4, 2023
- Reported
- October 11, 2023
- Ended
- August 6, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Oxybutynin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.